windows 7 ultimate cheapest price cheap ms office 2010 purchase office 2010 windows 7 home premium prices buy bento 3 cheap buy adobe dreamweaver 8 cost of adobe lightroom 2 purchase outlook online cheap software microsoft office 2013 cheap corel paint shop pro x2 ultimate buy tiger 10.4.0 mac purchase streets & trips cheapest roxio creator 2009 ultimate buy visio 2007 price of windows 7 business edition in india
cheapest photoshop cs5 purchase office 2003 product keys order windows xp sp2 cd buy and download dreamweaver cs5 for mac purchase microsoft office excel 2007 adobe muse cc 2014 prices purchase windows xp professional upgrade buy frontpage 2007 software purchase money 2008 best price toast mac best buy photoshop cs6 student best price adobe acrobat 9 buy acdsee classic adobe audition purchase buy windows 7 aus

Lymphoseek designated fast track status in head and neck cancer

Wed, Dec 11, 2013

Oral Cancer News

Source: www.empr.com
Author: press release

Navidea announced that the FDA has granted Fast Track designation to Lymphoseek (technetium 99m tilmanocept) Injection for sentinel lymph node detection in patients with head and neck cancer. Lymphoseek Injection is a novel, receptor-targeted, small-molecule radiopharmaceutical designed to identify the lymph nodes that drain from a primary tumor, which have the highest probability of harboring cancer.

Lymposeek Injection was evaluated in a prospective, open-label, multicenter, within-patient study (NEO3-06). It was designed to identify sentinel lymph nodes (SLNs) and determine the false negative rate (FNR) associated with Lymphoseek-identified SLNs relative to the pathological status of non-SLNs in head and neck and intraoral squamous cell carcinoma. The primary endpoint for the NEO3-06 trial was based on the number of subjects with pathology-positive lymph nodes following a multiple level lymph node dissection. A minimum of 38 subjects whose lymph nodes contained pathology-confirmed disease was required. Thirty nine subjects out of over 80 subjects enrolled were determined to have pathology-positive lymph nodes.

Navidea intends to file the supplemental New Drug Application (sNDA) for Lymphoseek before the end of 2013. Lymphoseek is already approved for use in lymphatic mapping to assist in the localization of lymph nodes draining a primary tumor in patients with breast cancer or melanoma.

Print Friendly
Be Sociable, Share!
, , ,

Leave a Reply

You must be logged in to post a comment.